Baron Funds Comments on Revance Therapeutics Inc

By
A A A

Revance Therapeutics, Inc. ( RVNC ), exemplifies the Fund's investments in biotechnology. Revance's initial product is a gel that the company is positioning as the first FDA-approved non-injectable form of Botox. We think many patients and doctors will prefer the gel over injectable Botox. In addition, its market is large and growing, especially internationally. (Allergan, which derives 80% of its revenue from sales of Botox, recently rejected a $53 billion takeover offer.) Product launch is scheduled for 2017 or earlier, and we expect that over time, Revance will capture 20-25% of the market.

From Baron Funds ' Second Quarter 2014 Shareholder Letter.
Read More:



About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .

This article first appeared on GuruFocus .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Stocks

Referenced Stocks: RVNC

GuruFocus

GuruFocus

More from GuruFocus:

Related Videos

Stocks

Referenced

Most Active by Volume

33,974,386
  • $17.98 ▲ 0.28%
20,763,901
  • $91.29 ▲ 2.06%
19,110,793
  • $7.26 ▼ 1.22%
18,528,869
    $8.33 unch
18,014,920
  • $4.19 ▼ 1.18%
16,448,919
  • $25.83 ▼ 0.19%
14,748,190
  • $7.60 ▼ 1.43%
14,144,383
  • $112.01 ▼ 0.47%
As of 12/24/2014, 02:12 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com